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Although hypophosphatemia has been implicated as a cause of respi- 
ratory failure, its impact on respiratory muscle function in patients 
hospitalized for other reasons remains to be determined. Maximal 
inspiratory pressures (MIP) and maximal expiratory pressures (MEP) 
were measured at the bedside in 23 hospitalized patients with serum 
phosphate levels less than 2.5 mg/dl, and these measurements were 
repeated daily during phosphate repletion until serum phosphate levels 
reached the normal range. A control group consisted of 11 normophos- 
phatemic inpatients. Sixteen of 23 hypophosphatemic patients, but 
none of the control patients (p <O.OOl), exhibited respiratory muscle 
weakness, defined as a MIP less than 40 cm Hz0 or a MEP less than 70 
cm H20. The mean initial MIP and MEP values were also significantly 
lower for the hypophosphatemic group. A significant correlation existed 
between initial phosphate level and initial MIP value (r = 0.50, p 
<0.02). With phosphate repletion, mean f SD MIP increased from 
-37 f 26 cm Hz0 to -49 f 24 cm Hz0 (p <0.003) and MEP from 60 
f 20 cm Hz0 to 69 f 19 cm HP0 (p <0.02). It is concluded that 
respiratory muscle weakness is common among hypophosphatemic 
patients and improves with phosphate repletion. 
Hypophosphatemia has been implicated as a cause of reversible acute 
respiratory failure [l-3] and has recently been shown to impair the 
contractile properties of the diaphragm [4]. Unfortunately, information 
about hypophosphatemia-associated respiratory muscle weakness is 
limited to patients in respiratory failure [l-4]. The significance of an 
incidental finding of hypophosphatemia in patients without respiratory 
failure has not been examined. We undertook the current study to 
prospectively evaluate the incidence of respiratory muscle weakness in 
hospitalized hypophosphatemic patients using bedside measurements of 
respiratory muscle strength. In addition, we wished to determine if 
respiratory muscle weakness improves with phosphate repletion. 
PA-DENTS AND METHODS 
From the Division of Pulmonary and Critical Care 
Medicine, University of Michigan and Veterans 
Administration Medical Centers, Ann Arbor, 
Michigan. Requests for reprints should be ad- 
dressed to Dr. Marc Peters-Golden, Division of 
Pulmonary and Critical Care Medicine, University 
of Michigan Medical Center, 3916 Taubman 
Center, Ann Arbor, Michigan 48109. Manuscript 
submitted June 29, 1987, and accepted in re- 
vised form March IO, 1988. 
Patients. Patients were recruited from the general medical and surgical 
services of the Ann Arbor Veterans Administration Medical Center during a 
30-day study period. Patients were selected for study on the basis of serum 
phosphate levels as identified from daily clinical chemistry records. The 
normal range of serum phosphate levels in our laboratory is 2.5 to 4.5 mg/ 
dl. All patients with a serum phosphate level of less than 2.5 mg/dl were 
eligible for the hypophosphatemic study group. Patients with a normal 
serum phosphate level were eligible for the normophosphatemic control 
group. Patients with known neuromuscular disease or who were within one 
week of major surgery were excluded from the study. Discretion was used 
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for the inclusion of critically ill patients and patients with 
cardiac disease, altered mental status, or psychiatric ill- 
ness that could limit their ability to adequately perform the 
necessary pulmonary function tests. Informed consent was 
obtained from all subjects and this study was approved by 
the Committee on Human Studies of the Ann Arbor Veter- 
ans Administration Medical Center. 
Fifty-four inpatients with hypophosphatemia were identi- 
fied in the 30-day period during which the study was per- 
formed. After application of the just described exclusion 
criteria, 24 eligible patients consented to participate. One 
hypophosphatemic patient was subsequently excluded 
from the study because after one week of phosphate sup- 
plementation he had not achieved a normal serum phos- 
phate level. On each of the first and last five days of the 
study period, two inpatients with normal serum phosphate 
levels were randomly selected from the clinical chemistry 
records for eligibility in the control group. After the exclu- 
sion criteria described earlier were applied, 11 normophos- 
phatemic patients consented to participate, and these pa- 
tients comprised the control group. 
Protocol. Upon entry into the study, the patients’ baseline 
respiratory muscle strength was assessed using maximal 
inspiratory pressures (MIP) and maximal expiratory pres- 
sures (MEP). Pressure measurements were determined 
from a dial manometer (R.F.M.D. Gauge, #395946, OEM 
Medical Inc., Richmond, Virginia) connected to a plastic 
cylinder that was fitted on the proximal end with a rubber 
mouthpiece similar to that described by Black and Hyatt 
[5]. The dial manometer records a maximum negative 
pressure reading of -80 cm Hz0 and a maximum positive 
pressure reading of 80 cm H20. Values exceeding the dial 
maxima were recorded as -80 or 80 cm H20, respectively. 
Measurements were made while the patients were sitting 
and wearing a noseclip. MIP was measured at the end of a 
tidal expiration and MEP was measured at near total lung 
capacity. The pressures measured were maintained for at 
least one second and the best of three efforts was record- 
ed. Reproducibility of these determinations was within IO 
percent for all patients. Forced vital capacity (FVC) and 
forced expiratory volume in one second (FEV,) were mea- 
sured using a portable digital spirometer (Eagle One, W.E. 
Collins Co., Braintree, Massachusetts). The best of three 
trials was recorded. 
Hypophosphatemic patients were given supplemental 
phosphorus in the form of Neutra-Phos capsules,, two cap- 
sules three times a day, until their serum phosphate level 
reached the normal range. Serum phosphate levels and 
MIP, MEP, FVC, and FEV, measurements were determined 
daily until a normal serum phosphate level was obtained. 
Control patients were not given Neutra-Phos capsules, but 
had daily measurements of serum phosphate, MIP, MEP, 
FVC, and FEV, for three days to assess the variability of 
these parameters and the possibility of a training effect as a 
cause of improvement in measured pulmonary function. 
Patients were defined as “weak” if they had a MIP less 
than 40 cm Hz0 or a MEP less than 70 cm H20. These 
criteria were arbitrarily defined relative to published normal 
values in healthy adult men [5-71. 
Hospital charts were reviewed to identify factors predis- 
posing to hypophosphatemia (intravenous dextrose infu- 
sion, total parenteral nutrition, antacid therapy, respiratory 
alkalosis, and diabetic ketoacidosis, among others) and to 
determine concomitant electrolyte or metabolic abnormali- 
ties. In addition, because of the known ability of theophyl- 
line [8], systemic beta-adrenergics [9], and digitalis [lo] 
to increase diaphragmatic contractility, use of these drugs 
was recorded. 
Statistical Analysis. Chi-square analysis was used to as- 
sess the significance of differences between prevalences 
in the two groups. Initial serum phosphate, MIP, MEP, FVC, 
and FEV, measurements were compared between hypo- 
phosphatemic and control patients using the upaired Stu- 
dent t-test. The correlation between MIP measurements and 
serum phosphate levels was assessed with linear regres- 
sion. Measurements of serum phosphate, respiratory mus- 
cle strength, and ventilatory function were compared pre- 
and post-phosphate repletion with the paired Student t-test. 
The same measurements were compared in control pa- 
tients at the beginning and end of their three-day trial. A p 
value of <0.05 was considered significant. All data are 
expressed as mean f SD. 
RESULTS 
During the study period, 1,939 serum phosphate determi- 
nations were processed by the laboratory, 137 (7.1 per- 
cent) of which were less than 2.5 mg/dl. These 137 
values originated from 92 patients, 54 of them inpatients. 
There were 1,145 inpatients at the Ann Arbor Veterans 
Administration Medical Center during the study period for 
a 4.7 percent overall prevalence of hypophosphatemia 
among inpatients. 
Table I shows the ages, duration of hospitalization at 
entry, and the major active diagnoses during the study 
period for all patients studied. There were no significant 
differences in age or the duration of hospitalization prior to 
study entry in the two groups. There were two women in 
the hypophosphatemic group and none in the normophos- 
phatemic group. Two of the hypophosphatemic patients 
required mechanical ventilation, one for chronic obstruc- 
tive pulmonary disease with respiratory failure and the 
second for gastrointestinal bleeding. There were no other 
significant metabolic abnormalities or any abnormalities 
in serum potassium, sodium, calcium, or magnesium 
levels found in any patient during the study period. A 
predisposing risk factor for hypophosphatemia could be 
identified in 20 of 23 hypophosphatemic patients and in 
eight of 11 normophosphatemic patients. The two most 
common factors found among all patients were antacid 
therapy (20 patients) and intravenous dextrose infusion 
(11 patients). 
The mean initial serum phosphate level for the hypo- 
phosphatemic patients was 1.9 f 0.4 mg/dl as com- 
pared with a value of 3.6 f 0.5 mg/dl (p <O.OOOOl) for 
the normophosphatemic control patients. By the criteria 
utilized, respiratory muscle weakness was found in 16 of 
23 hypophosphatemic patients and none of the 11 control 
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TABLE I Clinical Features of Patients 
Patient Age* 
Days Hospitalized 





































































Mean 63 12.4 


































Mean 57 8.5 
SD 15 8.2 
Syncope; history of pulmonary embolism 
Upper gastrointestinal bleed 
COPD exacerbation; car pulmonale 
Red cell aplasia; chest pain; atrial fibrillation 
Post-abdominal aortic aneurysm resection; COPD 
Alcohol withdrawal 
Cellulitis; Crohn’s disease 
COPD; Parkinson’s disease; diabetes mellitus 
Occipital lobe infarction; history of asthma 
Acute myelocytic leukemia 
Tuberculosis; history of esophageal carcinoma 
Alcoholic hepatitis; ascites 
Histiocytic lymphoma; streptococcal sepsis 
Post-resection of colon cancer 
Chronic diarrhea and weight loss 





Deep venous thrombosis 
Upper gastrointestinal bleed; carcinoma of tongue 
Respiratory arrest; COPD exacerbation 
Congestive failure 
Psoriasis; sleep apnea 
Chest pain 
Hemoptysis; new diagnosis of lung cancer 
Chemotherapy for astrocytoma 
Psoriasis; diabetes mellitus 
Congestive failure; diabetes mellitus; arrhythmias 
Scleroderma; car pulmonale 
Chest pain 
Mediastinal mass; history of cirrhosis 
Congestive failure 
COPD = chronic obstructive pulmonary disease. 
* There were no differences in mean age or days hospitalized at entry between the two groups. 
patients (p <O.OOl). The mean initial MIP value of the 
hypophosphatemic patients was significantly lower (p 
<0.03) than that of the normophosphatemic control pa- 
tients (-37 f 26 cm HP0 versus -57 f 16 cm H20, 
respectively) (Figure 1). In similar fashion, the mean 
initial MEP value of the hypophosphatemic patients was 
significantly lower (p <0.006) than that of the control 
patients (60 f 20 cm Hz0 versus 78 f 6 cm H20, 
respectively) (Figure 2). There was no significant differ- 
ence in mean FVC or FEV, measurements between the 
hypophosphatemic patients and the control patients 
(FVC: 2.47 f 1.1 liters versus 2.89 f 1.01 liters, 
respectively, and FEV,: 1.76 f 0.83 liters versus 2.34 f 
0.91 liters, respectively). Arterial blood gases were ob- 
tained for routine clinical indications in eight of the hypo- 
phosphatemic patients; the highest partial carbon dioxide 
pressure recorded was 42 mm Hg. 
There appeared to be a relationship between the de- 
gree of hypophosphatemia and the degree of respiratory 
muscle weakness when initial MIP measurements were 
plotted as a function of initial serum phosphate concentra- 
tion (r = 0.50, p <0.02) (Figure 3). Of the 12 patients 
with phosphate levels less than or equal to 2.0 mg/dl, 
nine demonstrated respiratory muscle weakness by our 
criteria. The four patients with serum phosphate levels 
below 1.5 mg/dl all had MIP values below or equal to 20 
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cm H20. When all serum phosphate and MIP values 
recorded in both groups during the entire study period 
were considered, a weaker but still significant correlation 
between phosphate and MIP persisted (r = 0.28, n = 
106, p <0.02). 
With phosphate repletion, the mean serum phosphate 
level increased in the hypophosphatemic patients from 
1.9 f 0.4 mg/dl to 3.5 f 0.8 mg/dl (p <O.OOOOl). 
Hypophosphatemic patients were repleted in 2.0 f 1.3 
days. The mean initial serum phosphate level of the 
control patients was 3.6 f 0.5 mg/dl and was 3.6 f 0.6 
mg/dl on the third day of the study. With phosphate 
repletion, the mean MIP value in the hypophosphatemic 
patient group increased from -37 f 26 cm H20 to -49 
f 24 cm Hz0 (p <0.003). For the normophosphatemic 
patient group, the mean initial MIP value was -57 f 16 
cm HP0 and was -55 f 15 cm Hz0 after three days of 
testing (p = NS). In similar fashion, there was a significant 
increase in the mean MEP measurement in the hypophos- 
phatemic patients that was not seen in the normophos- 
phatemic control patients (60 f 20 cm Hz0 to 69 f 19 
cm H20, p <0.02, and 78 f 6 cm Hz0 to 77 f 7 cm 
H20, p = NS, respectively). There were no significant 
differences in the FVC and FEV, measurements pre- and 
post-phosphate repletion in the hypophosphatemic pa- 
tients (FVC: 2.47 f 1.11 liters versus 2.50 f 1.02 liters 
respectively, and FEV,: 1.76 f 0.83 liters versus 1.8 1 f 
0.86 liters, respectively). Similarly, there were no 
changes in FVC and FEV, after three days of testing in the 
normophosphatemic control patients (FVC: 2.89 f 1.01 
liters versus 2.77 f 0.89 liters, respectively, and FEV,: 
2.34 f 0.91 liters versus 2.15 f 0.84 liters, respective- 
ly). No patients in either group received beta-adrenergic 
agents. One hypophosphatemic patient and two normo- 
phosphatemic patients were receiving digitalis at entry. 
Theophylline was used by four hypophosphatemic and 
two normophosphatemic patients at entry and continued 
during the study period in all of them. In only one hypo- 
phosphatemic patient was theophylline therapy instituted 
during the study period (Patient 1). 
There was no significant difference between the mean 
MIP value of the hypophosphatemic patients after phos- 
phate repletion (-49 f 24 cm H20) and that obtained 
after three days of testing in the normophosphatemic 
control patients (-55 f 15 cm H*O). There was also no 
significant difference between the mean MEP value in the 
hypophosphatemic patients following repletion (69 f 19 
cm H20) and that in the normophosphatemic patients on 
Day 3 (77 f 7 cm H*O). 
COMMENTS 
Our study corroborates previous estimates of the frequen- 
cy of hypophosphatemia in an adult inpatient population, 
and for the first time documents an increased incidence of 
respiratory muscle weakness in these patients using sim- 
ple measurements at the bedside. Furthermore, we have 
. . . 




Figure 1. MIP values for the hypophosphatemic patients 
and the normophosphatemic control patients. Note that 
pressures greater than -80 cm H20 are listed at -80 cm 
H20. Mean f SD values for the respective groups are 
1 
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Figure 2. MEP values for the hypophospha temic patients 
and the normophosphatemic control patients. Note that 
pressures greater than 80 cm H20 are listed at 80 cm H20. 
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Figure 3. MIP values at entryplottedas a function of initial 
serum phosphate concentrations for the hypophosphate- 
mic patients (0) and the normophosphatemic control pa- 
tients (0). (r = 0.50, p <0.02). 
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demonstrated that with phosphate repletion, respiratory 
muscle strength improves to the level found in normo- 
phosphatemic control patients. 
Previous studies have shown that hypophosphatemia is 
not an uncommon finding in an adult inpatient population 
and our prevalence figure of 4.7 percent if similar to that 
reported by others [ 11,12]. It should be noted that be- 
cause serum phosphate determinations may not have 
been performed on every inpatient, our prevalence figure 
represents an approximation. The prevalence of hypo- 
phosphatemia increases in those patients receiving ant- 
acids or intravenous dextrose, in patients with diabetic 
ketoacidosis, in patients withdrawing from alcohol; and in 
patients with a respiratory illness [ 1 l- 131. Similar predis- 
posing factors were seen in this study. 
normophosphatemic control patients. There also ap- 
peared to be a relationship between the degree of hypo- 
phosphatemia and the degree of respiratory muscle 
weakness at entry as illustrated by Figure 3, and through- 
out the study, when MIP measurements were plotted as a 
function of phosphate concentration. The weakest pa- 
tients had the lowest serum phosphate levels. With phos- 
phate repletion, mean MIP and MEP values were no longer 
significantly different from normophosphatemic control 
values. 
MIP and MEP measurements were selected as indica- 
tors of respiratory muscle strength because of their sensi- 
tivity and simplicity [7,14]. Our study has confirmed the 
fact that spirometric measurements, in contrast, are rela- 
tively insensitive indicators of respiratory muscle weak- 
ness [ 141. The manometer used in this study was de- 
signed to accurately show small changes in positive or 
negative pressure, but had the inherent limitation of a 
maximum pressure reading of + or -80 cm H20. As 
shown in Figures 1 and 2, this underestimated the true 
values in several patients in both groups. This limitation, 
however, tended to bias the data against demonstrating 
improvement in MIP and MEP values after phosphate 
repletion in the hypophosphatemic patients: three hypo- 
phosphatemic patients increased their MIP from a value 
below -80 cm Hz0 to a value greater than -80 cm Hz0 
as compared with one normophosphatemic patient after 
three days of testing. Seven hypophosphatemic patients 
increased their MEP from a value less than 80 cm HP0 to 
a value greater than 80 cm Hz0 as compared to one 
normophosphatemic patient. Using a manometer with the 
same sensitivity and a greater range would change the 
mean values, for MIP and MEP reported herein and would 
be expected to show a greater increase in respiratory 
muscle strength with phosphate repletion. 
Although we did not specifically match hypophospha- 
temic and normophosphatemic patients for severity of 
illness, selection on the basis of phosphate levels from 
daily clinical chemistry records should have minimized 
any bias in favor of noncomparability between the two 
groups. Indeed, the major diagnoses listed in Table I 
suggest comparable severities of illness between them. 
Moreover, as patients were not necessarily entered into 
the study on admission to the hospital (mean duration of 
hospitalization upon entry greater than one week for both 
groups), it is unlikely that the hypophosphatemic patients 
were more acutely ill at entry. Finally, patients who were 
uncooperative and unable to perform the tests were ex- 
cluded, and the high level of reproducibility in MIP and 
MEP values recorded strongly suggests that patients in the 
two groups were cooperative to a similar degree. 
We chose to measure MIP at near functional residual 
capacity rather than at residual volume because this is the 
lung volume at which tidal breathing occurs [7]. There is 
only one prior report of normal values for MIP at functional 
residual capacity where measurements ranged from -40 
cm Hz0 to greater than - 180 cm Hz0 with a mean of 
-78.8 cm Hz0 [6]. We therefore chose to define weak- 
ness conservatively as a MIP less than -40 cm H20. 
There is some variability in the reported normal range for 
MEP values in healthy adult men, with a suggested lower 
limit of normal of approximately 100 cm Hz0 [5,7,15]. 
We arbitrarily chose a value of 70 cm Hz0 or less to 
define weakness. Using these criteria, we found 16 of 23 
hypophosphatemic patients to evidence measurable res- 
piratory muscle weakness as compared with zero of 11 
For a number of reasons, we believe that respiratory 
muscle weakness was a function of hypophosphatemia, 
and that improvement was due to phosphate repletion: (1) 
As just indicated, we do not believe that the apparent 
respiratory muscle weakness in the hypophosphatemic 
patients can be explained merely by the fact that they 
were sicker and less able to cooperate. (2) A significant 
correlation existed between initial phosphate levels and 
initial MIP values. (3) No other electrolyte or metabolic 
abnormalities existed that might explain the weakness 
observed. (4) Although hypercapnia has been reported to 
impair diaphragmatic function [ 161, none of the eight 
hypophosphatemic patients on whom arterial blood gas 
measurements were available exhibited hypercapnia. (5) 
Improvement in MIP and MEP values with phosphorus 
repletion occurred within 48 hours in most of the hypo- 
phosphatemic patients, too rapid to be accounted for by 
changes in overall nutritional status. (6) There were no 
significant changes in spirometric values pre- and post- 
repletion, effectively excluding changes in obstructive 
airways disease or resolving acute bronchopulmonary 
disease as the cause for the improvement in respiratory 
muscle strength. (7) In only one hypophosphatemic pa- 
tient was treatment with a drug known to increase dia- 
phragmatic contractility (theophylline) initiated during the 
study period. This, along with the fact that the hypophos- 
phatemic patients exhibited improvements in MEP (re- 
flecting predominantly skeletal muscle function) as well 
as MIP (reflecting predominantly diaphragmatic function), 
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rule out the possibility that the observed improvements 
were attributable to drug therapy. (8) Finally, serial testing 
in normophosphatemic patients revealed no “training ef- 
fect” that might itself account for the improvement in MIP 
and MEP values observed in the hypophosphatemic pa- 
tients. 
Although our results unequivocally demonstrate respi- 
ratory muscle weakness in the hypophosphatemic pa- 
tients as compared with the normophosphatemic pa- 
tients, marked variability in MIP and MEP values was 
observed in the former. This most likely reflects the 
multiple determinants of respiratory muscle function, in- 
cluding not only phosphate level, but also serum potassi- 
um [ 171 and magnesium levels [ 181, acid-base status 
[ 16,191, nutritional status [20], oxygen delivery to the 
respiratory muscles [2 1,221, and length-tension relation- 
ships of the muscles [21,22]. Given that serum phosphate 
is only one of many factors that influence respiratory 
muscle function, it is not surprising that the correlation 
between phosphate level and MIP in our study was stron- 
ger when only initial (lower) phosphate values, rather than 
all values, were considered. The mechanism responsible 
for respiratory muscle weakness in hypophosphatemia is 
thought to be the diminution in the supply of high-energy 
phosphate compounds necessary for muscle contraction, 
and/or a reduction in the supply of 2,3-diphosphoglycer- 
ate leading to tissue hypoxia [23,24]. Although other 
factors must be corrected when identified, hypophospha- 
temia is easily reversible if recognized and treated appro- 
priately. 
The importance of recognizing hypophosphatemia-as- 
sociated respiratory muscle weakness is obvious in the 
patient with acute respiratory failure who cannot be 
weaned from mechanical ventilation. Recognizing occult 
respiratory muscle weakness has several important impli- 
cations. Early recognition of hypophosphatemia-associ- 
ated respiratory muscle weakness may allow repletion 
and improvement in respiratory muscle function before 
acute respiratory failure develops. Our hypophosphate- 
mic patients as a group demonstrated severe respiratory 
muscle weakness with a mean MIP of -37 cm H20. To 
place this value in perspective, a recent edition of one 
major pulmonary textbook lists a MIP value less than -25 
cm HP0 as one criterion for instituting mechanical ventila- 
tion [25]. In addition, MEP, which was significantly im- 
paired in the hypophosphatemic group, is an important 
determinant of an effective cough. An impaired cough 
may result in retained secretions, which may increase the 
patient’s susceptibility to a nosocomial respiratory infec- 
tion. 
Although hypophosphatemia has been implicated as 
the cause of acute respiratory failure in case reports, the 
prevalence of occult respiratory muscle weakness in 
hypophosphatemic patients without acute respiratory fail- 
ure has not previously been evaluated in a prospective 
manner. We have demonstrated that respiratory muscle 
weakness is a common occurrence in hospitalized pa- 
tients with incidentally detected hypophosphatemia and 
that the degree of respiratory muscle weakness can be 
severe. With phosphate repletion, respiratory muscle 
weakness improves. 
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